

MarÃ-a JosÃ© Soler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8914454/publications.pdf>

Version: 2024-02-01

135
papers

5,383
citations

109321

35
h-index

98798

67
g-index

141
all docs

141
docs citations

141
times ranked

7908
citing authors

#	ARTICLE	IF	CITATIONS
1	Haematological disorders following kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 409-420.	0.7	6
2	Anti-myeloperoxidase and proteinase 3 antibodies for nephritis flare prediction in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 697-704.	0.7	2
3	Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 5-13.	2.9	10
4	RICORS2040: the need for collaborative research in chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 372-387.	2.9	45
5	Negative immune responses to two-dose mRNA COVID-19 vaccines in renal allograft recipients assessed with simple antibody and interferon gamma release assay cellular monitoring. <i>American Journal of Transplantation</i> , 2022, 22, 786-800.	4.7	41
6	Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1868-1878.	0.7	43
7	Exploring Renal Changes after Bariatric Surgery in Patients with Severe Obesity. <i>Journal of Clinical Medicine</i> , 2022, 11, 728.	2.4	1
8	Antioxidant Roles of SGLT2 Inhibitors in the Kidney. <i>Biomolecules</i> , 2022, 12, 143.	4.0	16
9	Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 994-999.	0.7	14
10	Safety of Obtaining an Extra Biobank Kidney Biopsy Core. <i>Journal of Clinical Medicine</i> , 2022, 11, 1459.	2.4	0
11	Endothelial ADAM17 Expression in the Progression of Kidney Injury in an Obese Mouse Model of Pre-Diabetes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 221.	4.1	2
12	The COVID-19 pandemic: progress in nephrology. <i>Nature Reviews Nephrology</i> , 2022, 18, 80-81.	9.6	6
13	COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry. <i>Kidney360</i> , 2022, 3, 293-306.	2.1	10
14	Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression—real-world clinical practice. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1593-1600.	2.9	14
15	Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 872-876.	4.5	24
16	Kidney Biopsy in Patients with Cancer along the Last Decade: A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2915.	2.4	1
17	Diabetes and renal disease—should we biopsy?. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1384-1386.	0.7	15
18	Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1364-1370.	2.9	30

#	ARTICLE	IF	CITATIONS
19	Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers. CKJ: Clinical Kidney Journal, 2021, 14, 482-491.	2.9	12
20	Acute tubulointerstitial nephritis induced by checkpoint inhibitors versus classical acute tubulointerstitial nephritis: are they the same disease?. CKJ: Clinical Kidney Journal, 2021, 14, 884-890.	2.9	13
21	Infección por COVID-19 en una paciente con síndrome urticarial hipocomplementémico y vasculitis ANCA MPO en hemodiálisis tratada con omalizumab. Nefrología, 2021, 41, 354-356.	0.4	2
22	Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrology Dialysis Transplantation, 2021, 36, 87-94.	0.7	259
23	Albuminuria as a risk factor for mild cognitive impairment and dementia—what is the evidence?. Nephrology Dialysis Transplantation, 2021, 37, ii55-ii62.	0.7	14
24	Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors. Nephrology Dialysis Transplantation, 2021, , .	0.7	23
25	Role of C5aR1 and C5L2 Receptors in Ischemia-Reperfusion Injury. Journal of Clinical Medicine, 2021, 10, 974.	2.4	3
26	COVID-19 and its impact on the kidney and the nephrology community. CKJ: Clinical Kidney Journal, 2021, 14, i1-i5.	2.9	1
27	Tweet me: conferencing in the era of COVID-19 and 280 characters. CKJ: Clinical Kidney Journal, 2021, 14, 2142-2150.	2.9	3
28	A Specific Tubular ApoA-I Distribution Is Associated to FSGS Recurrence after Kidney Transplantation. Journal of Clinical Medicine, 2021, 10, 2174.	2.4	2
29	Diabetes, Albuminuria and the Kidney—Brain Axis. Journal of Clinical Medicine, 2021, 10, 2364.	2.4	9
30	Both Specific Endothelial and Proximal Tubular Adam17 Deletion Protect against Diabetic Nephropathy. International Journal of Molecular Sciences, 2021, 22, 5520.	4.1	8
31	COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab. Nefrología, 2021, 41, 354-355.	0.4	3
32	How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR. Journal of Clinical Medicine, 2021, 10, 2505.	2.4	17
33	COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study. Nephrology Dialysis Transplantation, 2021, 36, 2094-2105.	0.7	65
34	Renin-Angiotensin System Blockers and the Risk of COVID-19—Related Mortality in Patients with Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1061-1072.	4.5	7
35	Effect of ramipril on kidney, lung and heart ACE2 in a diabetic mice model. Molecular and Cellular Endocrinology, 2021, 529, 111263.	3.2	7
36	Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics. Nutrients, 2021, 13, 2559.	4.1	10

#	ARTICLE	IF	CITATIONS
37	SARS-CoV-2 vaccination in patients receiving kidney replacement therapies: where are we now with the protective immune response?. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1950-1954.	0.7	9
38	SARS-CoV-2 Infection Modulates ACE2 Function and Subsequent Inflammatory Responses in Swabs and Plasma of COVID-19 Patients. <i>Viruses</i> , 2021, 13, 1715.	3.3	14
39	Brain dysfunction in tubular and tubulointerstitial kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii46-ii55.	0.7	6
40	A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 23-35.	2.9	10
41	Acute kidney injury in patients treated with immune checkpoint inhibitors. , 2021, 9, e003467.		103
42	Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1833-1839.	4.5	27
43	Present and future of CONNECT: a new and compelling project of modern medicine. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii1-ii3.	0.7	0
44	Redefining the Role of ADAM17 in Renal Proximal Tubular Cells and Its Implications in an Obese Mouse Model of Pre-Diabetes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13093.	4.1	4
45	Circulating ADAMs are associated with renal and cardiovascular outcomes in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 130-138.	0.7	8
46	Mild cognitive impairment and kidney disease: clinical aspects. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 10-17.	0.7	38
47	MMP-10 is Increased in Early Stage Diabetic Kidney Disease and can be Reduced by Renin-Angiotensin System Blockade. <i>Scientific Reports</i> , 2020, 10, 26.	3.3	24
48	Risk Factors Associated with Major Complications after Ultrasound-Guided Percutaneous Renal Biopsy of Native Kidneys. <i>Kidney and Blood Pressure Research</i> , 2020, 45, 122-130.	2.0	25
49	SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 728-733.	2.9	68
50	Biopsia renal transyugular. La alternativa a la biopsia percutánea en pacientes de alto riesgo. <i>Nefrología</i> , 2020, 40, 634-639.	0.4	3
51	Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1941-1943.	6.1	95
52	COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1973-1983.	0.7	312
53	Nephrology: achieving sustainability. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2030-2033.	0.7	10
54	Impacto de la pandemia COVID-19 en los servicios de Nefrología españoles. <i>Nefrología</i> , 2020, 40, 579-584.	0.4	16

#	ARTICLE	IF	CITATIONS
55	Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology. Journal of the American Society of Nephrology: JASN, 2020, 31, 1380-1383.	6.1	453
56	Angiotensin-converting enzyme 2 influences pancreatic and renal function in diabetic mice. Laboratory Investigation, 2020, 100, 1169-1183.	3.7	25
57	SGLT2i and postglomerular vasodilation. Kidney International, 2020, 97, 805-806.	5.2	4
58	Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. Journal of Clinical Medicine, 2020, 9, 2030.	2.4	28
59	Risk factors for non-diabetic renal disease in diabetic patients. CKJ: Clinical Kidney Journal, 2020, 13, 380-388.	2.9	14
60	Matrix Metalloproteinases in Diabetic Kidney Disease. Journal of Clinical Medicine, 2020, 9, 472.	2.4	65
61	Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, i13-i23.	0.7	26
62	Is There Decreasing Public Interest in Renal Transplantation? A Google Trends™ Analysis. Journal of Clinical Medicine, 2020, 9, 1048.	2.4	1
63	ADAM17 inhibition may exert a protective effect on COVID-19. Nephrology Dialysis Transplantation, 2020, 35, 1071-1072.	0.7	98
64	Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 714-716.	4.5	74
65	GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. Journal of Clinical Medicine, 2020, 9, 947.	2.4	85
66	Coronavirus disease 2019 in chronic kidney disease. CKJ: Clinical Kidney Journal, 2020, 13, 297-306.	2.9	59
67	Revisiting Experimental Models of Diabetic Nephropathy. International Journal of Molecular Sciences, 2020, 21, 3587.	4.1	46
68	Utility of transjugular renal biopsy as an alternative to percutaneous biopsy. Nefrologia, 2020, 40, 634-639.	0.4	1
69	Impact of COVID-19 pandemic in Spanish Nephrology Services. Nefrologia, 2020, 40, 579-584.	0.4	4
70	Should high molecular weight forms of apolipoprotein A-I be analyzed in urine of relapsing FSGS patients?. Pediatric Nephrology, 2019, 34, 2423-2424.	1.7	3
71	Crying kidneys: Bilateral renal contrast leak. Journal of Onco-Nephrology, 2019, 3, 171-173.	0.6	0
72	Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe. Nephrology Dialysis Transplantation, 2019, 34, 1469-1480.	0.7	8

#	ARTICLE	IF	CITATIONS
73	The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes. <i>Journal of Clinical Medicine</i> , 2019, 8, 864.	2.4	17
74	Role of ADAM17 in kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, F333-F342.	2.7	37
75	Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 313-321.	2.9	35
76	Sodium-glucose cotransporter inhibitors: beyond glycaemic control. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 322-325.	2.9	23
77	Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1112-1114.	0.7	27
78	Apolipoprotein A-Ib as a biomarker of focal segmental glomerulosclerosis recurrence after kidney transplantation: diagnostic performance and assessment of its prognostic value - a multi-centre cohort study. <i>Transplant International</i> , 2019, 32, 313-322.	1.6	22
79	Advances in understanding the role of angiotensin-regulated proteins in kidney diseases. <i>Expert Review of Proteomics</i> , 2019, 16, 77-92.	3.0	22
80	Sex hormones and their influence on chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 1-9.	2.0	74
81	ACE2 and ACE in acute and chronic rejection after human heart transplantation. <i>International Journal of Cardiology</i> , 2019, 275, 59-64.	1.7	10
82	<i>Lancet</i> Countdown paper: what does it mean for nephrology?. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 4-6.	0.7	4
83	Anti-phospholipase A2 receptor antibody and spontaneous remission in membranous nephropathy. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 33-35.	2.9	8
84	Single-cell RNA profiling of glomerular cells in diabetic kidney: a step forward for understanding diabetic nephropathy. <i>Annals of Translational Medicine</i> , 2019, 7, S340-S340.	1.7	5
85	The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease. <i>Nefrología</i> , 2018, 38, 197-206.	0.4	5
86	Impact of Recurrent Acute Kidney Injury on Patient Outcomes. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 34-44.	2.0	37
87	Short- and long-term outcomes after non-severe acute kidney injury. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 61-67.	1.6	26
88	Effect of renin-angiotensin-aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 12-22.	0.7	39
89	The effect of associative strength on semantic priming in schizophrenia. <i>Psychiatry Research</i> , 2018, 259, 1-6.	3.3	4
90	Bloqueo del sistema renina-angiotensina-aldosterona en pacientes con enfermedad renal diab�tica avanzada. <i>Nefrología</i> , 2018, 38, 197-206.	0.4	8

#	ARTICLE	IF	CITATIONS
91	Membrane Attack Complex and Factor H in Humans with Acute Kidney Injury. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 1655-1665.	2.0	10
92	Treatment for hepatitis C virus-associated mixed cryoglobulinaemia. <i>The Cochrane Library</i> , 2018, 5, CD011403.	2.8	8
93	Sex dimorphism in ANGII-mediated crosstalk between ACE2 and ACE in diabetic nephropathy. <i>Laboratory Investigation</i> , 2018, 98, 1237-1249.	3.7	36
94	The current role of renal biopsy in diabetic patients. <i>Minerva Medica</i> , 2018, 109, 116-125.	0.9	25
95	Stable Isotope Labeling with Amino Acids (SILAC)-Based Proteomics of Primary Human Kidney Cells Reveals a Novel Link between Male Sex Hormones and Impaired Energy Metabolism in Diabetic Kidney Disease. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 368-385.	3.8	13
96	Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?. <i>CKJ: Clinical Kidney Journal</i> , 2017, 10, 320-322.	2.9	10
97	La conexión reno-cardiovascular en el paciente con diabetes mellitus: ¿qué hay de nuevo?. <i>Endocrinología, Diabetes Y Nutrición</i> , 2017, 64, 237-240.	0.3	2
98	The reno-cardiovascular connection in the patient with Diabetes mellitus: What's new?. <i>Endocrinología Diabetes Y Nutrición (English Ed)</i> , 2017, 64, 237-240.	0.2	2
99	The large spectrum of renal disease in diabetic patients. <i>CKJ: Clinical Kidney Journal</i> , 2017, 10, sfw137.	2.9	12
100	Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse. <i>International Journal of Molecular Sciences</i> , 2017, 18, 563.	4.1	215
101	Gonadectomy prevents the increase in blood pressure and glomerular injury in angiotensin-converting enzyme 2 knockout diabetic male mice. Effects on renin-angiotensin system. <i>Journal of Hypertension</i> , 2016, 34, 1752-1765.	0.5	19
102	Predictive factors for non-diabetic nephropathy in diabetic patients. The utility of renal biopsy. <i>Nefrología</i> , 2016, 36, 535-544.	0.4	14
103	RAS and sex differences in diabetic nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, F945-F957.	2.7	43
104	Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, F534-F546.	2.7	51
105	Factores predictivos de nefropatía no diabética en pacientes diabéticos. Utilidad de la biopsia renal. <i>Nefrología</i> , 2016, 36, 535-544.	0.4	20
106	Circulating angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with chronic kidney disease. <i>Atherosclerosis</i> , 2016, 253, 135-143.	0.8	33
107	Glycosylation Profile of IgG in Moderate Kidney Dysfunction. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 933-941.	6.1	75
108	SP472RISK FACTORS FOR NON-DIABETIC NEPHROPATHY IN DIABETIC PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii535-iii536.	0.7	0

#	ARTICLE	IF	CITATIONS
109	Endothelin Blockade in Diabetic Kidney Disease. <i>Journal of Clinical Medicine</i> , 2015, 4, 1171-1192.	2.4	39
110	SP086GLYCOSILATION PROFILE OF IMMUNOGLOBULIN G IN EARLY CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii407-iii407.	0.7	0
111	Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1176-1185.	0.7	85
112	Implicit memory functioning in schizophrenia: Explaining inconsistent findings of word stem completion tasks. <i>Psychiatry Research</i> , 2015, 226, 347-351.	3.3	4
113	Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR < 45 mL/min). <i>Nephrology Dialysis Transplantation</i> , 2015, 30, ii1-ii142.	0.7	113
114	Renin-angiotensin system within the diabetic podocyte. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 308, F1-F10.	2.7	50
115	Albumin inhibits the insulin-mediated ACE2 increase in cultured podocytes. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 306, F1327-F1334.	2.7	18
116	Effect of Insulin on ACE2 Activity and Kidney Function in the Non-Obese Diabetic Mouse. <i>PLoS ONE</i> , 2014, 9, e84683.	2.5	45
117	ACE2 alterations in kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2687-2697.	0.7	105
118	Circulating Angiotensin-Converting Enzyme 2 Activity in Kidney Transplantation: A Longitudinal Pilot Study. <i>Nephron</i> , 2013, 121, c144-c150.	1.8	25
119	Role of Circulating Angiotensin Converting Enzyme 2 in Left Ventricular Remodeling following Myocardial Infarction: A Prospective Controlled Study. <i>PLoS ONE</i> , 2013, 8, e61695.	2.5	73
120	Protein/creatinine ratio in spot urine versus 24-hour urine protein. <i>Nefrologia</i> , 2013, 33, 134-5.	0.4	1
121	New Experimental Models of Diabetic Nephropathy in Mice Models of Type 2 Diabetes: Efforts to Replicate Human Nephropathy. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-9.	3.8	62
122	New options and perspectives for proteinuria management after kidney transplantation. <i>Transplantation Reviews</i> , 2012, 26, 44-52.	2.9	10
123	ACE2 and Diabetes: ACE of ACEs?. <i>Diabetes</i> , 2010, 59, 2994-2996.	0.6	95
124	Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, F398-F405.	2.7	188
125	Pharmacologic modulation of ACE2 expression. <i>Current Hypertension Reports</i> , 2008, 10, 410-4.	3.5	69
126	Angiotensin-converting enzyme 2 and the kidney. <i>Experimental Physiology</i> , 2008, 93, 549-556.	2.0	38

#	ARTICLE	IF	CITATIONS
127	Putative endothelial progenitor cells are associated with flow-mediated dilation in refractory hypertensives. <i>Blood Pressure</i> , 2008, 17, 298-305.	1.5	14
128	New aspects of the renin-angiotensin system: angiotensin-converting enzyme 2 a potential target for treatment of hypertension and diabetic nephropathy. <i>Current Opinion in Nephrology and Hypertension</i> , 2008, 17, 250-257.	2.0	30
129	Acid-Base and Potassium Disorders in Liver Disease. <i>Seminars in Nephrology</i> , 2006, 26, 466-470.	1.6	46
130	ACE and ACE2 Activity in Diabetic Mice. <i>Diabetes</i> , 2006, 55, 2132-2139.	0.6	270
131	Glomerular Localization and Expression of Angiotensin-Converting Enzyme 2 and Angiotensin-Converting Enzyme. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 3067-3075.	6.1	439
132	Circulating Endothelial Progenitor Cells After Kidney Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 2154-2159.	4.7	22
133	Association of renin-angiotensin system blockers with COVID-19 diagnosis and prognosis in patients with hypertension: a population-based study. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	2.9	6
134	Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	6
135	Mortality in elderly patients starting hemodialysis program. <i>Seminars in Dialysis</i> , 0, , .	1.3	0